Michael Egger, MD
Psychiatry · Omaha, NENPI 1144370131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 195 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$584
- Otsuka America Pharmaceutical, Inc.$541
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$282
- Johnson & Johnson$267
- Neurocrine Biosciences, Inc.$196
- Lundbeck LLC$190
- plus $955 from 15 others
What the payments were for
- Food & beverage$2,96598%
- Education$512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,016 in reported general payments places this provider in the 80th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $247,205 |
| AristadaAripiprazole Lauroxil | 32 | $111,833 |
| AustedoDeutetrabenazine | 19 | $42,099 |
| RexultiBrexpiprazole | 23 | $37,356 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $32,669 |
| CaplytaLumateperone Tosylate | 11 | $30,414 |
| VraylarCariprazine Hcl | 18 | $27,685 |
| Aripiprazole | 90 | $5,927 |
| Quetiapine Fumarate | 168 | $5,604 |
| Lurasidone Hcl | 35 | $5,506 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $5,355 |
| BelsomraSuvorexant | 11 | $4,695 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 30 | $4,044 |
| Bupropion Hcl SrBupropion Hcl | 60 | $3,527 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 14 | $3,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $196 | $247,20529 claims |
| Alkermes, Inc.Aristada, Lybalvi | $584 | $144,50153 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $92 | $42,09919 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $541 | $37,35623 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $282 | $30,41411 claims |
| AbbVieVraylar | $14 | $27,68518 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $74 | $5,35512 claims |
| MerckBelsomra | $27 | $4,69511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Omaha
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Syed SattarOmaha$16K
- Michael SedlacekOmaha$15K
- Sriram RamaswamyOmaha$13K
- Elizabeth FitzpatrickOmaha$10K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.